Anti-Müllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer

Journal of Cancer Survivorship

Volumn 8, Issue 4, 2014, Pages 548-554

  Charpentier, Anne Marie ^a,b   Chong, Amy Lee ^c   Gingras Hill, Genevieve ^a   Ahmed, Sameera ^a   Cigsar, Candemir ^d   Gupta, Abha A ^b   Greenblatt, Ellen ^e,f   Hodgson, David C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti M llerian hormone; Childhood cancer survivors; Fertility; Ovarian reserve

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MORTALITY; NEOPLASMS; OVARIAN RESERVE; SURVIVOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-MULLERIAN HORMONE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; NEOPLASMS; OVARIAN RESERVE; SURVIVORS; YOUNG ADULT;

EID: 84936772475     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-014-0364-4     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. (eds). SEER cancer statistics review, 1975–2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
3. Green DM, Sklar CA, Boice Jr JD, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2374–81.
4. Homan GF, Davies M, Norman R. The impact of lifestyle factors on reproductive performance in the general population and those undergoing infertility treatment: a review. Hum Reprod Update. 2007;13(3):209–23.
5. Metwally M, Li TC, Ledger WL. The impact of obesity on female reproductive function. Obes Rev. 2007;8(6):515–23.
6. Leridon H. Demographic effects of the introduction of steroid contraception in developed countries. Hum Reprod Update. 2006;12(5):603–16.
7. van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause. 2004;11(6 Pt 1):601–6.
8. van Disseldorp J, Faddy MJ, Themmen AP, de Jong FH, Peeters PH, van der Schouw YT, et al. Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab. 2008;93(6):2129–34.
9. Anderson RA. What does anti-Mullerian hormone tell you about ovarian function? Clin Endocrinol (Oxf). 2012;77(5):652–5.
10. Grynnerup AG, Lindhard A, Sorensen S. The role of anti-Mullerian hormone in female fertility and infertility—an overview. Acta Obstet Gynecol Scand. 2012;91(11):1252–60.
11. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003;18(11):2368–74.
12. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP, Hakvoort-Cammel FG, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin’s lymphoma during childhood. J Clin Endocrinol Metab. 2007;92(10):3869–74.
13. Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod. 2009;24(4):982–90.
14. Miyoshi Y, Ohta H, Namba N, Tachibana M, Miyamura T, Miyashita E, et al. Low serum concentrations of anti-mullerian hormone are common in 53 female childhood cancer survivors. Horm Res Paediatr. 2013;79(1):17–21. doi:10.1159/000346139.
15. Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2014;61(1):53–67. doi:10.1002/pbc.24679.
16. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(16):2677–85.
17. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8(6):331–41.
18. The Practice Committees of the American Society for Reproductive Medicine, the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37–43.
19. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17(12):3065–71.
20. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod. 2007;22(9):2414–21.
21. Mauz-Korholz C, Hasenclever D, Dorffel W, Ruschke K, Pelz T, Voigt A, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28(23):3680–6.
22. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008;90(2):395–400.
23. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007;134(2):196–201.
24. Deb S, Campbell BK, Pincott-Allen C, Clewes JS, Cumberpatch G, Raine-Fenning NJ. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Mullerian hormone and small antral follicle count using three-dimensional ultrasound. Ultrasound Obstet Gynecol. 2012;39(5):574–80.
25. van den Berg MH, van Dulmen-den Broeder E, Overbeek A, Twisk JW, Schats R, van Leeuwen FE, et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Hum Reprod. 2010;25(6):1520–7.
26. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024.
27. van Dorp W, van den Heuvel-Eibrink MM, Stolk L, Pieters R, Uitterlinden AG, Visser JA, et al. Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum Reprod. 2013;28(4):1069–76.